SCHEMBL21964543

SCHEMBL21964543

Cc1c(N)cnn1CC1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EED O75530 1/20 0.43
RBBP4 Q09028 1/20 0.43
SUZ12 Q15022 1/20 0.43
EZH2 Q15910 1/20 0.43
AEBP2 Q6ZN18 1/20 0.43
PDE8B O95263 1/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.38
ADORA2A P29274 1/20 0.37
PDE1A P54750 2/20 0.35
PDE1B Q01064 2/20 0.35
PDE1C Q14123 2/20 0.35
CTSD P07339 1/20 0.35
CTSE P14091 1/20 0.35
BACE1 P56817 1/20 0.35
CDC7 O00311 1/20 0.35
TLR7 Q9NYK1 2/20 0.34
NR3C1 P04150 1/20 0.34
MAP3K14 Q99558 1/20 0.34
BRD4 O60885 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17076641 0.89 PKM (0.43) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL6156218 0.85 PKM (0.48) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16985255 0.84 LMNA (0.35) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL17459025 0.84 PKM (0.54) LMNAPKMADORA2APDE1APDE1B
SCHEMBL17458924 0.76 LMNA (0.40) LMNAPKMMAPTRAB9AKMT2A
SCHEMBL21961356 0.75 PDE8B (0.39) PDE8BPDE1APDE1BPDE1CCTSD
SCHEMBL25857669 0.75 PKM (0.44) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16985426 0.73 MAPT (0.43) LMNAADORA2AMAPT
SCHEMBL16212583 0.73 LMNA (0.60) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL9941718 0.73 DDB1 (0.40) PDE8BPKMADORA2ACDC7RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136311-B2 Heteroaromatic derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-10-05 US disclosed
EP-3478675-B1 HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136311-B2 Heteroaromatic derivatives as NIK inhibitors NFKBIA, IKBKG, IKBKE EED 1606/4885RBBP4 770/4885SUZ12 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.